



**Contact Information:**  
 Eleanor Haglund (CEO)  
 908-303-3903  
[eleanor@halomountain.com](mailto:eleanor@halomountain.com)

**Product:** Therapeutic targeting Alzheimer's disease inflammation

**Management and Advisors:**

Eleanor Haglund, CEO, Former experience in biotech and pharmaceuticals

Rudolph Tanzi, PhD, Harvard Brain Science Initiative, Co-Director of the Center for Brain Health at

Massachusetts General Hospital

Dean Slack, Director of New Products Planning & Strategy at J&J and Bayer

Sid O'Bryant, PhD, Executive Director, Institute for Translational Neuroscience Research, University of North Texas

Kevin Kelly, MD, PhD, Director of Neuroscience Research at Allegheny General Hospital

**Amount and Type of Financing**

**Sought:** \$2.5 M to get to IND  
 Funded to date through accelerator funding and angel investment

**Milestones:**

2018: Accelerator and Angel Investment Obtained

2019: Pre-clinical studies to start

2021: IND received, Phase I Clinical to starts

2022: Phase I completed, Phase II Clinical to start

2024: Clinical efficacy endpoint

2025: Acquisition by large pharmaceutical company


**Corporate Overview:**

DE C-Corp, 2018

**Business Overview:** Halo Mountain is developing a treatment to lengthen life span and improve quality of life for people with Alzheimer's disease (AD). Halo Mountain's proposed treatment protects cells from that neurodegeneration. Recent research has shown that there is a subgroup of 20-25% of all AD patients that has extensive inflammatory and metabolic dysfunction. Halo Mountain's approach directly addresses the desperate clinical need in AD for an effective early-stage treatment.

**Clinical Need and Market Opportunity:**

- 44 million people with Alzheimer's disease worldwide
- 500,000 people diagnosed with early stage AD each year
- 25% of these patients have intense inflammatory dysfunction
- Limited options for treatment
- Alzheimer's disease companies over the last five years have sold after their Phase II clinical trials for between \$55 M and \$3.5 B



**Company Technology and Solution:** This therapeutic is an orally available drug that is expected to be safe and to stop cognitive decline in a targeted subgroup of Alzheimer's disease patients.

This formula is based on proven results and known compounds.

1. Ongoing clinical trials, using a similar method to treat Parkinson's disease at Massachusetts General Hospital, demonstrated that the treatment can slow the disease (Parkinson Study Group SURE-PD Investigators, 2017).
2. Trials in Multiple Sclerosis have shown cessation, of the disease pathology by using a similar method of treatment (Spitsin et al., 2001).
3. A significant decrease in purines in the blood and cerebrospinal fluid in multiple sclerosis and Parkinson's patients are an inverse risk factor for the disease (Dujmovic et al., 2009; Ascherio et al. 2009).

This data supports the therapeutic use of our formula to restore normal metabolic levels in Alzheimer's disease brains to protect cells from oxidative damage.

**Competition and Advantage:** Alzheimer's disease patients are currently using medications that have limited efficacy and unpleasant side effects, like cholinesterase inhibitors (Aricept) and NMDA receptor inhibitors (Namenda). Combined these two drugs make up 80% of the annual market. Halo Mountain's patented formula will be successful because it focuses not on enhancing cholinergic neurotransmission or diminishing excitotoxicity, but rather on enhancing a mechanism to raise purine levels. We are pursuing a composition of matter new formulation patent.

